- /
- Supported exchanges
- / US
- / CRL.NYSE
Charles River Laboratories (CRL NYSE) stock market data APIs
Charles River Laboratories Financial Data Overview
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. In additionally, It has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. The company was founded in 1947 and is headquartered in Wilmington
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Charles River Laboratories (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Charles River Laboratories data using free add-ons & libraries
Get Charles River Laboratories Fundamental Data
Charles River Laboratories Fundamental data includes:
- Net Revenue: 4 024 M
- EBITDA: 801 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: 2.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Charles River Laboratories News
New
Charles River Labs (CRL): Assessing Valuation Following Recent Volatility and Share Price Recovery
Charles River Laboratories International (CRL) shares edged up slightly, with investors watching for updates that could guide the laboratory services provider's outlook. The stock has moved 1% higher ...
CRL Q3 Deep Dive: Portfolio Streamlining and End Market Stabilization Shape Outlook
Lab services company Charles River Laboratories (NYSE:CRL) reported Q3 CY2025 results beating Wall Street’s revenue expectations , but sales were flat year on year at $1.00 billion. Its non-GAAP pro...
Charles River Laboratories International Inc (CRL) Q3 2025 Earnings Call Highlights: Strategic ...
This article first appeared on GuruFocus. Release Date: November 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Charl...
Charles River Laboratories outlines $1B buyback, targets $70M cost savings and divestitures amid strategic review
Earnings Call Insights: Charles River Laboratories International, Inc. (CRL) Q3 2025 MANAGEMENT VIEW * CEO James Foster announced, "the Board strongly supports the company's strategic direction an...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.